

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A combination comprising
(i) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, also named TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; and (ii) a tenofovir or its prodrug tenofovir disoproxil fumarate; and (iii) emtricitabine; wherein said TMC278, said tenofovir its prodrug tenofovir disoproxil fumarate and said emtricitabine are present in therapeutically effective amounts that can be administered once daily to treat HIV.
2. Canceled.
3. Canceled.
4. Canceled.
5. Canceled.
6. (Previously Presented) The combination according to claim 1, wherein TMC278 occurs in its E-isomeric form.
7. Canceled.
8. Canceled.
9. Canceled.
10. Canceled.

11. Canceled.
12. Canceled.
13. Canceled.
14. Canceled.
15. Canceled.
16. Canceled.
17. Canceled.
18. Canceled.
19. (Previously Presented) The combination according to claim 1 wherein weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/4 to 4/1.
20. (Previously Presented) A product containing a combination as claimed in claim 1 as a combined preparation for simultaneous, separate or sequential use against HIV infection.
21. (Previously Presented) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as claimed in claim 1.
22. Canceled.
23. Canceled.

24. (Previously Presented) A method of preventing HIV infection comprising administering the combination as claimed in claim 1.
25. (Previously Presented) A kit, comprising the combination of claim 1 packaged with instructions for use.
26. (Previously Presented) The combination of claim 1, wherein said TMC278, said tenofovir or its prodrug tenofovir disoproxil fumarate and said emtricitabine are each in separate pharmaceutically acceptable carriers.
27. (Previously Presented) The combination of claim 26, wherein said pharmaceutically acceptable carrier is selected from the group consisting of tablets, capsules, parenteral compositions, injectable solutions, and injectable suspensions.
28. (Previously Presented) The combination of claim 1, wherein said TMC278, said tenofovir or its prodrug tenofovir disoproxil fumarate and said emtricitabine are together in a single pharmaceutically acceptable carrier.
29. (Previously Presented) The combination of claim 28, wherein said pharmaceutically acceptable carrier is selected from the group consisting of tablets, capsules, parenteral compositions, injectable solutions, and injectable suspensions.